Medicinal cannabis hub
Information about access pathways for medicinal cannabis products.
Last updated
The medicinal cannabis hub provides information on the regulation of medicinal cannabis in Australia along with guidance material and information resources for individuals and patients, health professionals, and sponsors.
Most medicinal cannabis goods are unapproved goods. Unapproved goods have not been assessed by us for safety, quality, performance or effectiveness.
Where clinically appropriate, there are pathways for registered health professionals to access unapproved medicinal cannabis goods for their patients.
The 2024 vaping reforms resulted in some changes to the regulation of vaping devices that are intended to be used to vape medicinal cannabis.
More information
- Process to include a medicinal cannabis vaping device or cannabis device accessory on the ARTG
- Applications and reporting
- Medicinal cannabis product list
- Resources, clinical trials and clinical evidence
- Presentation: TGO93 testing and regulation of medicinal cannabis
- Medicinal cannabis - guidance documents
Frequently asked questions
- Access to medicinal cannabis products
- Accessing medicinal cannabis for a patient
- Importation, manufacture and supply of unapproved medicinal cannabis products
Data
Reforms
- Webinar presentation: Medicinal cannabis - Changes to Special Access Scheme (SAS) and Authorised Prescriber applications, 22 November 2021
- Webinar presentation: Medicinal cannabis - Changes to sponsor requirements for supplying unapproved medicinal cannabis products in Australia, 22 November 2021
- Webinar presentation: Medicinal cannabis - Changes to Special Access Scheme (SAS) and Authorised Prescriber applications, 23 November 2021
- Webinar: Medicinal cannabis reforms
Product types
Latest articles
-
What to know if you've been prescribed medicinal cannabis
Understanding the difference between an approved and unapproved therapeutic good can help you make informed decisions and have meaningful conversations with your healthcare practitioner, especially when considering treatments like medicinal cannabis. -
Do your patients know the risks of unapproved medicinal cannabis products?
Medicinal cannabis prescribing in Australia has increased significantly in recent years. However, many patients are unaware that most medicinal cannabis products are unapproved goods. As a prescriber, you play a critical role in ensuring patients are informed, protected and supported when these products are being considered for their clinical situation. -
Dispensed Pty Ltd issued infringement notices and directed to cease alleged unlawful advertising of medicinal cannabis
We have issued 6 infringement notices, totalling $118,800, and a direction notice to Dispensed Pty Ltd (Dispensed) for the alleged unlawful advertising of medicinal cannabis.
Latest publications
-
Clarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).
-
Medicinal cannabis products are permitted to be supplied into Australia under the Special Access Scheme, by authorised prescribers, and/or for use in clinical trials.
-
This publication outlines our plan to transition to a paperless model for Special Access Scheme (SAS) and Authorised Prescriber (AP) submissions. From 1 July 2024 we will only accept submissions via the SAS/AP Online System.